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Abstract The intraductal approach is particularly appeal-
ing in the setting of ductal carcinoma in situ (DCIS), a
preinvasive breast neoplasm that is thought to be entirely
intraductal in its extent. Based on an emerging understand-
ing of the anatomy of the ductal system as well as novel
techniques to leverage the access accorded by the intra-
ductal approach, researchers are actively exploring how
ductal lavage, ductoscopy, and intraductal infusion of
therapeutic agents may enhance breast cancer treatment.
Both cytologic and molecular diagnostics continue to
improve, and work is ongoing to identify the most effective
diagnostic biomarkers for DCIS and cancer, although
optimal targeting of the diseased duct remains an important
consideration. Ductoscopy holds potential in detection of
occult intraductal lesions, and ductoscopically guided lump-
ectomy could increase the likelihood of a more comprehen-
sive surgical excision. Exciting pilot studies are in progress to
determine the safety and feasibility of intraductal chemother-
apy infusion. These studies are an important starting point for
future investigations of intraductal ablative therapy for DCIS,
because as our knowledge and techniques evolve, it is likely
that DCIS may be the target most amenable to treatment by
intraductal therapy. If such studies are successful, these
approaches will allow an important and meaningful transfor-
mation in treatment options for women diagnosed with DCIS.
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Introduction
Ductal carcinoma in situ (DCIS) is the most common
noninvasive lesion of the breast. It is defined as the
proliferation of malignant ductal epithelial cells without
penetration of the basement membrane. Greater use of
screening mammography over the past few decades has led
to increasing diagnosis of DCIS such that the incidence of
DCIS increased from 1.87 per 100,000 women from 1973
to 1975 to 32.5 per 100,000 women in 2004 [1].
Approximately 25% of breast cancers currently diagnosed
by mammography in the United States are classified as
DCIS, and it has been estimated that more than 1 million
women in the United States alone will be living with a
diagnosis of DCIS by 2020 [1]. Despite the increasing
prevalence and high mammographic detection rates, the
natural history of DCIS continues to be poorly understood.
The linear model of breast carcinogenesis suggests that
DCIS is an intermediate step between normal healthy breast
tissue and invasive breast cancer [2]. Although a few
retrospective studies evaluating misdiagnosed or biopsy
only treatment of DCIS indicate that some 14% to 53% of
patients will progress to invasive cancer without treatment,
virtually no prospective data have been obtained regarding
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progression of untreated disease [3–6]. Substantial data
indicate that recurrence rates for patients with DCIS are
dramatically reduced after excision or mastectomy. Standard
therapy for DCIS is surgical excision, with 31% of women
treated with mastectomy, 28% with breast-conserving
surgery alone, and 40% with breast-conservation therapy
and radiotherapy [7]. In a study by Silverstein et al. [8]
comparing local recurrence among patients with DCIS,
7-year disease-free survival rates were approximately 98%
in those choosing mastectomy versus 84% in those
receiving breast-conservation surgery with radiation.
However, this same study, as well as others, has failed
to show a survival benefit from any treatment modality
used to treat DCIS [8].
Because patient perception of the risk of developing
local recurrence or dying of breast cancer does not differ
significantly whether diagnosed with DCIS or invasive
breast cancer [9, 10], it can be inferred that patients will
continue to pursue aggressive therapies that could pose
considerable emotional and physical impact. Recent advan-
ces in technology and the development of new treatment
modalities for DCIS have exploited the intraductal nonsys-
temic nature of DCIS by focusing on treatments specifically
targeted to intraductal delivery. It is hoped that as these
approaches are developed, patients will be provided less
invasive treatment options for this disease. The intraductal
approach includes procedures and technologies such as
nipple aspiration, ductal lavage, ductoscopy, and most
recently, the introduction of antineoplastic treatment agents
directly into the ductal-alveolar unit for both diagnosis and
treatment of DCIS. This review focuses on the intraductal
approach to the diagnosis and treatment of breast cancer,
with a specific emphasis on its role in the management of
DCIS.
Breast Ductal Anatomy
The study of breast duct anatomy dates back to 1840, with
Cooper’s studies injecting colored wax into the ducts of
over 200 breasts of women who died during lactation [11].
He described human breast tissue as organized into separate
lobes consisting of one central duct, its peripheral branches,
and associated glandular tissue [11]. Subsequent to this
report, a considerable number of studies using histologic,
ductal, and imaging approaches have been conducted in an
effort to describe the number and arrangement of ducts
composing the human mammary gland [12].
Reports of breast and nipple duct anatomy vary depend-
ing on whether the study focused on openings on the nipple
that can be cannulated in vivo or in vitro and followed into
functional ducts in the breast or the number of duct profiles
seen on cross-sections of the nipple. Original histologic
studies and anatomy texts describe breast anatomy as
radially symmetrical lobes with 15 to 20 central ducts.
Ductogram studies by Sartorius and Smith demonstrated 5
to 9 ducts per breast, whereas Teboul and Halliwell
described 15 to 20 ducts converging on 5 to 8 milk pores
in a series of more than 6,000 breasts studied via ultrasound
and ductoscopy [13]. Moffat and Going’s [14] three-
dimensional (3D) computer model of a single autopsy
breast traced 10 complete nonanastamosing ductal systems.
Using six separate approaches, Love and Barsky [15] found
that more than 90% of the nipples examined in their studies
contained 5 to 9 ductal orifices. The distribution consisted
of nonanastamosing central ducts that travel back toward
the chest wall and peripheral ducts that drape over the
central ducts in a radial fashion [15].
As a result of these and similar studies, it is now
generally accepted that the ductal tree is a nonanastamosing
system comprised of central ducts leading back to the chest
wall and peripheral ducts draping over the central ducts.
However, discrepancies remain regarding the number of
ducts found on histologic cross sections and 3D image
modeling versus the number of ducts visible and
available for cannulation at the nipple surface. It still
remains unclear whether these inconsistencies represent
ductal branching close to the nipple surface or ducts
with associated sebaceous glands, all of which have
implications for intraductal approaches to management
[16, 17].
Intraductal Lavage
The study of breast ductal fluid via nipple aspiration began
in the 1950s, but the low yield of epithelial cells for
cytologic analysis essentially precluded it as an efficient
tool for diagnosis. In 2001, Dooley et al. [18] demonstrated
significant success in producing cytologically evaluable
fluid in ductal lavage specimens compared with nipple
aspiration. The median epithelial yield from nipple aspira-
tion was 120 cells per breast, whereas the yield with ductal
lavage was 13,500 cells per duct [18]. Like nipple
aspiration, ductal lavage is based on the principle that
invasive breast cancer develops via a linear progression
through intraductal precursor lesions, and that these lesions
are located in the fluid-containing ducts. Accordingly, many
have sought to discover whether ductal lavage may have a
particular role in both diagnosis and treatment of intraductal
cancers, which should be especially accessible via intra-
ductal strategies.
A number of long-term follow-up studies have con-
firmed that the presence of ductal cellular atypia constitutes
a risk factor for breast cancer. In a 17-year follow-up study,
Page et al. [19] found that women with atypia on biopsy
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had 5.3 times the risk of developing invasive disease
compared with women with nonproliferative lesions on
biopsy. Wrensch et al. [20, 21] associated cellular atypia in
nipple aspiration fluid with a 4.9-fold higher relative risk
than those women who produced no nipple fluid. Fabian
et al. [22] used periareolar fine needle aspiration to assess
women for the presence of atypia and found that 15% of
women with an elevated Gail risk and atypia developed
cancer compared with 4% of women with similar Gail risk
but no atypia. Thus, the utility of ductal cytology in breast
cancer risk stratification has been established, but the
accuracy of ductal lavage for diagnosis of DCIS and
invasive cancer remains a question. Investigators have
evaluated the potential of both cytology and biomarker
assessment of lavage fluid in this regard.
Cytology of Intraductal Aspirates
Because of the association of nipple aspirate fluid
production and breast cancer risk, an assumption was
made that fluid-yielding ducts were those most likely to
harbor disease, and lavage of these ducts would yield cells
with cytologic atypia corresponding to histologic abnor-
malities. However, multiple studies assessing the utility of
cytologic evaluation have concluded that the ducts with
precancerous or cancerous lesions are not necessarily more
likely to yield fluid, and in addition, that the low sensitivity
in detecting high-grade atypical cells makes cytologic
evaluation of ductal lavage specimens a low-yield tool for
assessing risk or identifying existing in situ or invasive
breast cancer.
In women with known cancer undergoing mastectomy,
Khan et al. [23] found that only 38% of cancer-containing
ducts yielded ductal fluid for analysis, and Maddux et al.
[24] determined that atypia rates were similar for both fluid-
producing and dry ducts (19% vs 15%). In Khan et al.’s
study [23], only 36% of the fluid-containing ducts yielded
ductal lavage specimens with marked atypia or malignancy,
thus making the overall sensitivity for detecting cancer
approximately 13%. Brogi et al. [25] showed a similar
sensitivity of 14% in their study of premastectomy ductal
lavage on 26 cancer-containing breasts. Although a recent
study by Wood et al. [26] found that nipple aspiration fluid
was more commonly expressed in cancerous compared
with unaffected breasts, overall sensitivity for detecting
marked atypia or malignant cells in affected breasts was
similar to previous studies, at approximately 17%.
Sartorius et al. [27] had proposed that with increasingly
large invasive cancers, the ducts might become obstructed
and epithelial cells with higher-grade atypia may extrava-
sate into surrounding tissues rather than shed into the ductal
system. If this were the case, early noninvasive lesions such
as DCIS would be more likely to yield atypical epithelial
cells in lavage specimen. Interestingly, Chatterton et al. [28]
did find that the presence of DCIS in the central ducts close
to the nipple and the size of DCIS were independent
predictors of atypical cytology, but most of the samples
demonstrated only mild atypia on cytologic evaluation. In a
follow-up study, Khan et al. [29] included only women with
calcifications on mammogram, thus increasing the proba-
bility of DCIS lesions. Of the 10 women diagnosed
histologically with DCIS, only one woman produced nipple
fluid from a DCIS-bearing duct, and the cytology was
benign [29]. These findings corroborate results of the
earlier studies and suggest low overall utility for cytologic
evaluation of ductal lavage, even in the setting of known
DCIS.
Molecular Biomarkers in Lavage Fluid
Due to the relatively low yield of cytologic evaluation for
breast cancer diagnosis, many groups have now focused on
molecular biomarkers in ductal lavage fluid to identify
characteristics specific to precancerous and cancerous
lesions of the breast. Current studies analyzing genetic,
epigenetic, and proteomic attributes of cells in ductal lavage
fluid have suggested that biomarker analysis may be a more
sensitive tool than cytology alone, because molecular
biomarker changes often precede morphologic alterations
and their detection might lead to earlier identification of
cells at risk for malignant change.
Some investigators have used fluorescence in situ
hybridization (FISH) to detect genomic abnormalities by
identifying aneusomy of chromosomes within ductal lavage
cells, as changes in copy numbers of chromosomes 1, 8, 11,
and 17 have been shown to be associated with both
preinvasive and invasive breast lesions. King et al. [30]
described aneusomy for these chromosomes in 71% of the
specimens from malignant cases and in 11% from benign
cases, for a sensitivity of 71% and specificity of 89%.
Krishnamurthy et al. [31] evaluated the utility of using
FISH as an adjunct to cytologic evaluation. They confirmed
chromosomal aneuploidy in all of the malignant and
markedly atypical cases, but found aneusomy in only one
case described by cytology as mildly atypical. The authors
concluded that FISH-based detection of chromosomal
aneuploidy could potentially be used as an adjunct to
cytologic evaluation in confirming both benign and
malignant diagnoses [31]. Adduci et al. [32] utilized
array-based comparative genomic hybridization (CGH) in
primary surgical specimens then tested matched ductal
lavage specimens with region-specific FISH probes to
determine whether similar chromosomal alterations were
present in both specimens. Although only 11% of cytology
samples were characterized as malignant, 55% of samples
showed biomarker changes that were identical to those
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found in the primary surgical specimen. This study clearly
demonstrated the increased sensitivity of molecular probes
over cytology for detection of malignancy in ductal lavage
samples [32].
Genomic and epigenomic markers have also been
examined. Using quantitative fluorescence image analysis,
Zhang et al. [33] evaluated lavage specimens from women
with both benign and malignant findings and demonstrated
100% sensitivity in detecting cancer using DNA5cER and
G-actin expression. Others have shown that evaluation of
methylation may also have more sensitivity for cancer
detection than cytology: Krassenstein et al. [34] used a
panel of six loci to detect hypermethylation of CpG islands
in matched tissue and nipple aspiration fluid samples. They
detected hypermethylation in all of the malignant tissue and
82% of the fluid samples [34]. Fackler et al. [35] utilized
quantitative multiplex methylation-specific polymerase
chain reaction (QM-PCR) to evaluate promoter methylation
events in a panel of genes believed to be associated with
increased breast cancer risk. In their evaluation of QM-PCR
versus cytologic evaluation, QM-PCR had double the rate
of detection of cancer cells.
Proteomic analyses using the surface-enhanced laser
desorption and ionization-time of light/mass spectrometry
(SELDI-TOF-MS) technique have also been conducted on
lavage fluid with success. Sauter et al. [36] prospectively
collected nipple aspiration fluid from women scheduled for
diagnostic breast surgery and identified three protein peaks
associated with the pathologic categories of atypical ductal
hyperplasia, DCIS, and invasive disease. With identifica-
tion of additional proteins, this method may become a new
tool for tumor detection.
At this time, the overall utility of nipple fluid as a tool
for risk assessment and early detection of breast cancer
remains controversial. Technical limitations of cannulation
include duct perforation and lavage of non-cancer-
containing ducts. Analysis of ductal fluid by cytology has
been shown to have low sensitivity, with ambiguous
predictive value associated with findings of mild atypia.
However, the potential use of molecular biomarkers as a
comprehensive panel or as an adjunct to cytologic analysis
will continue to improve the diagnostic utility of ductal
lavage as a minimally invasive method for risk assessment
and early detection of breast cancer lesions.
Ductoscopy
Clearly, another way to exploit the access provided by the
ductal system is through direct endoscopic visualization of the
ductal tree, which may afford a novel approach to intraductal
lesions such as DCIS. Although mammary ductoscopy (MD)
has not yet garnered widespread use, tremendous improve-
ments in endoscope technology in the past decade have
allowed for unprecedented visualization and access to the
intraluminal duct (Fig. 1). Both in the United States and Asia,
MD has had the greatest utility in the setting of pathologic
nipple discharge. Currently available endoscopes measure
0.55 to 0.9 cm in external diameter, often with a working
side port that allows for snaring and extraction of ductal
lesions. Investigators have shown that MD-guided extraction
is effective for benign intraductal papillomas, but less
effective in removing malignant lesions, including DCIS.
Uchida et al. [37] have suggested two reasons for this
observation, including a stiff and noncompliant ductal wall
that is resistant to forceps biopsy, and the distal location of
malignant lesions, many of which are located in the
peripheral terminal ductal-lobular units.
In evaluation of abnormal nipple discharge, ductoscopy
has been shown to be of benefit by avoiding the need for
preoperative ductogram. One series reported that 61% of
ducts with discharge had abnormal endoscopic findings that
were surgically excised with ductoscopic guidance [38••].
Of the six cancers diagnosed, four had had negative
preoperative radiographic work-up. In patients with known
DCIS or breast cancer, ductoscopic guidance has been
shown to improve reexcision rates. Dooley et al. [39••]
have had extensive experience with this technique, and in
their hands, lumpectomy for early-stage cancers guided by
ductoscopy had a markedly reduced likelihood of local
failure compared with standard lumpectomy techniques. As
scope technology continues to improve, ductoscopy may
a. Normal duct b. Low grade DCIS
Fig. 1 Intraductal endoscopy.
Current endoscopic technology
has allowed high resolution visu-
alization of intraductal anatomy
and intraluminal abnormalities. a
Normal duct, demonstrating
smooth ductal walls and ductal
bifurcation. b Exophytic lesion
seen on ductoscopy of a duct
with pathologic nipple discharge.
Pathology of the excised lesion
showed low-grade ductal carci-
noma in situ (DCIS)
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prove to be a useful localization option to guide resection of
nonpalpable intraductal cancers.
Intraductal Therapy
Because most breast cancers arise from ductal epithelial
cells, enormous opportunities exist in targeting therapy
directly into the ductal system. Additionally, intraductal
therapy is less likely to cause systemic toxicity and adverse
effects. Currently, there are a number of phase 1 feasibility
and safety trials evaluating the intraductal approach to
breast cancer prevention and treatment.
Current clinical trials are based on intriguing initial animal
studies by Murata et al. [40] that involved intraductal
administration of the active tamoxifen metabolite 4-
hydroxytamoxifen (4-OHT) and pegylated liposomal doxo-
rubicin (PLD) into transgenic mouse models of breast cancer.
Results from the study demonstrated that not only was the
intraductal administration of chemopreventive or chemother-
apeutic drugs significantly more effective in preventing
tumor development and promoting tumor regression, but
there were also lower circulating levels of the agents and, as
a result, no evidence of systemic toxicity. 4-OHTwas found to
be as effective as subcutaneous tamoxifen in the prevention of
tumors, and intraductal administration of PLD caused
complete regression in 24 of 25 tumors with a tumor-free
3-month follow-up period. PLD was also found to be
protective against tumor formation. Toxicity studies showed
no myelosuppression and peak levels of drug were signifi-
cantly lower for intraductal versus intravenous injection.
As a result of the encouraging efficacy and safety data
from these animal studies, a number of clinical trials are
being conducted to explore the possibility of intraductal
therapy in humans, primarily in the setting of DCIS or
early-stage invasive cancer. Stearns et al. [41] at Johns
Hopkins University School of Medicine have completed a
phase 1 trial to determine the feasibility, safety, and
maximum tolerated dose of PLD administered into one
duct of women awaiting mastectomy. Preliminary data
reveal that doxorubicin concentrations were not detectable
in plasma, nipple aspirate fluid, or breast tissue [41].
Although histologic findings have not yet been reported,
the safety of this intervention in women awaiting surgery
for cancer appears promising.
In a similar Phase 1 study, Love and colleagues [42, 43]
conducted a dose-escalation study in Beijing, China to
determine safety and evaluate histopathologic response to
either intraductal carboplatin or PLD instilled into 5 to 8 ducts
in 32 women 2 to7 days prior to mastectomy for breast cancer.
Three dose levels were used, with the highest level approach-
ing the dose used intravenously. At the highest doses of PLD,
patients experienced tenderness and mild erythema and breast
swelling, but no serious adverse events were noted. In the
carboplatin group, both inflammatory responses and epithelial
changes increased in a dose-dependent fashion. In the PLD
group, no inflammatory changes were seen, but there was a
marked increase of epithelial response to PLD treatment
compared with the carboplatin-treated patients, including
epithelial attenuation in the terminal ductal-lobular units
(Fig. 2).
In a study directly targeted to test the practicality and
efficacy of intraductal PLD treatment for DCIS, Love and
Mahoney [44••] are testing intraductal PLD in the neo-
adjuvant setting. In patients with core biopsy-proven DCIS,
20 mg of PLD (10 cm3) is injected intraductally followed
Fig. 2 Mastectomy specimen in a patient treated with intraductal
pegylated liposomal doxorubicin (PLD). All patients in the study
underwent surgery 2 to 5 days following PLD administration.
Cannulated ducts were concurrently injected with dye to enable
identification of treated ducts on pathologic evaluation. a Surgical
specimen with delineation of treated ducts by dye. The extent of
ductal branching is clearly seen. b Hematoxylin and eosin (H&E)-
stained section of treated duct (left) adjacent to untreated duct (right).
The treated duct shows signs of marked epithelial atresia in response
to PLD injection
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by a 6-week observation period before scheduled surgery.
The study end points are regression of the lesion on surgical
pathology, decreased markers in ductal fluid, and changes
on MRI before and after treatment. Thus far, four patients
have received the full drug dose into the duct harboring
DCIS, with two women reporting mild to moderate breast
inflammatory reactions that responded to anti-inflammatory
medications. Initial evaluation of histology of surgical
specimens has confirmed a tissue response of inflammation,
squamous metaplasia, and fat necrosis [44••]. This trial
continues to accrue patients, and the investigators plan to
collect data on tissue markers in the DCIS as well as in the
cell pellet specimens collected at the time of PLD injection.
Although women in this study will undergo surgery, the
long-term implications of the trial may be to facilitate future
treatment of DCIS with intraductal therapy alone. In
addition, if this approach is effective in stripping cancer
precursor cells from the ducts, intraductal injection of
ablative agents in unaffected, high-risk women may allow
for true loco-regional chemoprevention.
Ductal Lavage for Monitoring DCIS
Lavage biomarkers have been evaluated as potential indica-
tors of response to systemic treatment, particularly in regard to
analysis during repeat sampling in chemopreventive studies.
Bhandare et al. [45] evaluated ductal lavage specimens from
145 high-risk women and found significant positive correla-
tions between atypical cytology, epithelial cell number, and
levels of the estrogen-related biomarkers Ki-67, estrogen
receptorα, and cyclooxygenase-2. As a follow-up study,
these investigators conducted a phase 2 trial assessing the
utility of ductal lavage to measure biomarkers of tamoxifen
action [46••]. Of 182 women with Gail risk higher than 1.7%
recruited to the study, 63% underwent entry and repeat
ductal lavage and 47% had sufficient cells for analysis at
both the initial and the follow-up lavage; 46 women chose
observation and 39 women chose tamoxifen. The expected
reduction in estrogen-related biomarkers was observed for
Ki-67 and estrogen receptorα, but not in cyclooxygenase-2
in the tamoxifen-treated group. Additionally, cytologic
findings showed a trend toward improvement in the
tamoxifen group. Although the biomarker and cytologic
profiles improved during the tamoxifen treatment, and thus
seem to suggest clinical utility in this method of monitoring,
the attrition rate and difficulty with obtaining adequate
samples on repeat lavage make it necessary to re-evaluate
this method [47]. However, as DCIS treatment evolves
towards less invasive management strategies, women opting
for active surveillance for DCIS may in the future be offered
ductal lavage to monitor for cancer progression or response
to systemic treatments.
Conclusions
The intraductal approach to the breast offers a unique
opportunity to diagnose, study, and treat DCIS, a highly
prevalent preinvasive lesion that is entirely confined within
the ductal system. Additional studies are necessary to further
elucidate the ductal system of the breast as well as the
common anatomic distribution of DCIS within the system.
The utility of intraductal lavage as a tool in the diagnosis and
treatment of DCIS will hinge upon technologic advances that
will allow for easier and more specific cannulation of affected
ducts and continued research to establish a panel of
biomarkers in addition to cytology that can reliably indicate
disease. Thus far, small pilot trials have demonstrated that
intraductal therapy is feasible and can be safely administered,
and we await clinical trials of intraductal therapy alone to
better evaluate the potential of this new and exciting
therapeutic modality. The intraductal approach is of particular
interest for disease confined to the ducts that does not require
systemic therapy. It is hoped that continued advancements will
offer women with breast cancer a minimally invasive way to
detect breast disease, as well as in future allow for an
important adjunct to surgical treatment for DCIS.
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